Clinical trial
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or…
NCT00402181 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00402181 |
|---|---|
| Title | An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase 2 Multicenter Study of CNTO 328 (Anti IL-6 Monoclonal Antibody) in Subjects With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Biological, Drug |
| Interventions | Siltuximab, Dexamethasone |
| Enrollment | 53 |
| Start date | Oct 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Nov 22, 2006 |
| Last update posted | May 14, 2014 |
| Countries | Netherlands, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: